GlassScriptPhysician profile
Russell Akin
NPI 1346432440
$6,923.91
in general payments reported to CMS, 2019-2025
35 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $383 · 2021: $1,221 · 2022: $1,179 · 2023: $1,392 · 2024: $1,191 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,870.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,118.34 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $954.59 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $862.35 | 2020-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $553.15 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $535.90 | 2020-2025 | |
| Lilly USA, LLC | $294.00 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $266.22 | 2022-2024 | Sotyktu |
| Convatec INC. | $199.70 | 2024-2025 | |
| Incyte Corporation | $188.43 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $186.85 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $186.43 | 2019-2025 | Nemluvio, Oracea, Twyneo |
| Sun Pharmaceutical Industries INC. | $174.11 | 2021-2025 | Ilumya |
| Kerecis Limited | $159.57 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pfizer INC. | $144.91 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $137.64 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $123.15 | 2023-2025 | Adbry, Anzupgo |
| Almirall LLC | $109.02 | 2022-2025 | Klisyri, Seysara |
| Genzyme Corporation | $96.85 | 2019-2024 | |
| Biofrontera INC. | $59.24 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $58.87 | 2025 | Bimzelx |
| Icad, INC | $58.80 | 2021 | |
| Organon LLC | $56.63 | 2025 | Vtama |
| Misonix INC | $48.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.39 | 2023-2024 | Spevigo |
| Journey Medical Corporation | $44.79 | 2022-2023 | |
| Genentech USA, INC. | $43.08 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.82 | 2020-2021 | |
| Lifenet Health | $33.19 | 2023 | |
| Allergan, INC. | $24.00 | 2021 | |
| Kyowa Kirin, INC. | $23.37 | 2025 | |
| Merck Sharp & Dohme LLC | $22.86 | 2023 | Keytruda |
| Dermira, INC. | $21.31 | 2020 | |
| Bioventus LLC | $18.14 | 2022 | |
| Krystal Biotech INC | $16.59 | 2025 | Vyjuvek |
| Organogenesis INC. | $14.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Akin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.